Andreas Hottinger

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


55 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2005 | 2000 | 1999 | 1997 | 1994 |
 
Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
Darlix A., Mandonnet E., Freyschlag C.F., Pinggera D., Forster M.T., Voss M., Steinbach J., Loughrey C., Goodden J., Banna G. et al., 2019/07. Neuro-oncology practice, 6 (4) pp. 264-273. Peer-reviewed.
 
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C., Desbaillets N., Hottinger A.F., 2019/06. Current opinion in neurology, 32 (3) pp. 500-510. Peer-reviewed.
 
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.
Hottinger A.F., Bensaid D., De Micheli R., Moura B., Mokhtari K., Cardoso E., Idbaih A., Stupp R., 2019/01/01. Annals of oncology, 30 (1) pp. 155-156. Peer-reviewed.
 
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
Wirsching H.G., Tabatabai G., Roelcke U., Hottinger A.F., Jörger F., Schmid A., Plasswilm L., Schrimpf D., Mancao C., Capper D. et al., 2018/06/01. Annals of oncology, 29 (6) pp. 1423-1430. Peer-reviewed.
Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis.
Hottinger A.F., de Micheli R., Guido V., Karampera A., Hagmann P., Du Pasquier R., 2018/03. Neurology, 5 (2) pp. e439. Peer-reviewed.
 
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Astaras C., de Micheli R., Moura B., Hundsberger T., Hottinger A.F., 2018/02/01. Current neurology and neuroscience reports, 18 (1) p. 3. Peer-reviewed.
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A., Read W., Steinberg D.M., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K. et al., 2017/12/19. JAMA, 318 (23) pp. 2306-2316. Peer-reviewed.
 
Nouvelle classification OMS 2016 des gliomes : quels changements ? [Revised WHO classification 2016 of gliomas : what's new ?]
Brouland J.P., Hottinger A.F., 2017/10/18. Revue medicale suisse, 13 (579) pp. 1805-1809. Peer-reviewed.
 
Extra central nervous system metastases from glioblastoma: a new possible trigger event?
Simonetti G., Silvani A., Fariselli L., Hottinger A.F., Pesce G.A., Prada F., Gaviani P., 2017/06/24. Neurological sciences, 38 (10) pp. 1873-1875. Peer-reviewed.
 
Neurologie [Neurology]
Maulucci F., Benninger D., Démonet J.F., Du Pasquier R.A., Hirt L., Hottinger A., Kuntzer T., Michel P., Nater B., Novy J. et al., 2017/01/11. Revue medicale suisse, 13 (544-545) pp. 79-83. Peer-reviewed.
Current management of low-grade gliomas.
Hottinger A.F., Hegi M.E., Baumert B.G., 2016/12. Current opinion in neurology, 29 (6) pp. 782-788. Peer-reviewed.
 
Neurologic complications of immune checkpoint inhibitors.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) pp. 806-812. Peer-reviewed.
 
Neurooncology: a Swiss army knife specialty.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) p. 781. Peer-reviewed.
Tumor treating fields: a novel treatment modality and its use in brain tumors.
Hottinger A.F., Pacheco P., Stupp R., 2016/10. Neuro-oncology, 18 (10) pp. 1338-1349. Peer-reviewed.
 
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Espeli V., Ruegg E., Hottinger A.F., Modarressi A., Dietrich P.Y., 2016/05. Anticancer research, 36 (5) pp. 2359-2364. Peer-reviewed.
 
Prise en charge des tumeurs cérébrales primaires: une approche multidisciplinaire [Multidisciplinar approach to the management of gliomas]
Moura B., Migliorini D., Bourhis J., Daniel R., Levivier M., Hottinger A.F., 2016/04/27. Revue medicale suisse, 12 (516) pp. 821-825.
 
Recent advances in the management of atypical meningiomas.
Messerer M., Richoz B., Cossu G., Dhermain F., Hottinger A.F., Parker F., Levivier M., Daniel R.T., 2016/04. Neuro-Chirurgie, 62 (4) pp. 213-222. Peer-reviewed.
Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V., Pomoni A., Hottinger A., Nicod-Lalonde M., Prior J.O., 2016/03. Neuro-oncology, 18 (3) pp. 426-434. Peer-reviewed.
Multilevel severe radiculopathy from an extraneural glioblastoma cervical metastasis.
Starnoni D., Yamgoué Y., Hottinger A., Bartanusz V., 2016. Surgical neurology international, 7 (Suppl 40) pp. S1028-S1029. Peer-reviewed.
 
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.
Hundsberger T., Hottinger A.F., Roelcke U., Roth P., Migliorini D., Dietrich P.Y., Conen K., Pesce G., Hermann E., Pica A. et al., 2016. Journal of Neuro-oncology, 126 (1) pp. 175-183. Peer-reviewed.
 
Cerebriforms cells in cerebrum: an unusual finding
Sarro R., Gaide O., Letourneau A., Missiaglia E., Bisig B., Hottinger A., Cairoli A., de Leval L., 2015. p. 633 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
 
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K., Bessell E., Bromberg J., Hottinger A.F., Preusser M., Rudà R., Schlegel U., Siegal T., Soussain C., Abacioglu U. et al., 2015. Lancet. Oncology, 16 (7) pp. e322-e332. Peer-reviewed.
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L. et al., 2015. JAMA, 314 (23) pp. 2535-2543. Peer-reviewed.
 
Recent developments and controversies in primary central nervous system lymphoma.
Hottinger A.F., Alentorn A., Hoang-Xuan K., 2015. Current Opinion In Oncology, 27 (6) pp. 496-501. Peer-reviewed.
 
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Hundsberger T., Tonder M., Hottinger A., Brügge D., Roelcke U., Putora P.M., Stupp R., Weller M., 2014. Journal of Neuro-Oncology, 118 (2) pp. 321-328.
 
Isolated cerebral metastasis of a triceps muscle leiomyosarcoma: A case report.
Gautschi O.P., Hottinger A.F., Lobrinus J.A., Schaller K., Bijlenga P., 2014. British Journal of Neurosurgery, 28 (3) pp. 400-402.
 
Niedrig-gradige Gliome im Erwachsenenalter [Low-grade gliomas in adults].
Kratzsch T., Gautschi O.P., Kuhn S.A., Hottinger A.F., Hildebrandt G., Stienen M.N., 2014. Praxis, 103 (23) pp. 1385-1396. Peer-reviewed.
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Hottinger A.F., Aissa A.B., Espeli V., Squiban D., Dunkel N., Vargas M.I., Hundsberger T., Mach N., Schaller K., Weber D.C. et al., 2014. British Journal of Cancer, 110 (11) pp. 2655-2661.
Standards of care and novel approaches in the management of glioblastoma multiforme.
Hottinger A.F., Stupp R., Homicsko K., 2014. Chinese Journal of Cancer, 33 (1) pp. 32-39. Peer-reviewed.
 
Anticorps antineuronaux: un domaine en plein développement [Anti-neuronal antibodies: a rapidly developing field].
Zekeridou A., Rossetti A.O., Hottinger A.F., Du Pasquier R.A., 2013. Revue Médicale Suisse, 9 (384) pp. 909-914.
 
Biphasic response of a teco-mesencephalic pylocitic astrocytoma after gamma knife surgery, a report of a case
Tuleasca C., Negretti L., Magaddino V., Maeder P., Hottinger A., Borruat F.X., Levivier M., 2013. dans 11th International Stereotactic Radiosurgery Society Congress.
 
High-grade meningiomas: new avenues for drug treatment?
Preusser M., Berghoff A.S., Hottinger A.F., 2013. Current Opinion in Neurology, 26 (6) pp. 708-715. Peer-reviewed.
 
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A., Chan T.A., Abrey L.E., Khasraw M., Reiner A.S., Kaley T.J., DeAngelis L.M., Lassman A.B., Nolan C.P., Gavrilovic I.T. et al., 2013. Neuro-oncology, 15 (2) pp. 242-250.
 
A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.
Hottinger A.F., George A.C., Bel M., Favet L., Combescure C., Meier S., Grillet S., Posfay-Barbe K., Kaiser L., Siegrist C.A. et al., 2012. Oncologist, 17 (3) pp. 436-445. Peer-reviewed.
 
Decision making and management of gliomas: practical considerations.
Hottinger A.F., Homicsko K., Negretti L., Lhermitte B., Stupp R., 2012. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 23 Suppl 10 pp. x33-x40.
 
Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis.
Hottinger A.F., Favet L., Pache J.C., Martin J.B., Dietrich P.Y., 2011/04/06. Case reports in oncology, 4 (1) pp. 211-215. Peer-reviewed.
 
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S., Elandt K., Greil R., Hottinger A.F., Huber U., Lemke D., Marosi C., Ochsenbein A., Pichler J., Roelcke U. et al., 2011. Acta Oncologica (stockholm, Sweden), 50 (5) pp. 630-635. Peer-reviewed.
 
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.
Iwamoto F.M., Hottinger A.F., Karimi S., Riedel E., Dantis J., Jahdi M., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Journal of Neuro-oncology, 105 (3) pp. 607-612.
 
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto F.M., Hottinger A.F., Karimi S., Riedel E., Dantis J., Jahdi M., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Neuro-oncology, 13 (11) pp. 1244-1251. Peer-reviewed.
 
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
Hottinger A.F., Iwamoto F.M., Karimi S., Riedel E., Dantis J., Park J., Panageas K.S., Lassman A.B., Abrey L.E., Fleisher M. et al., 2011. Annals of Neurology, 70 (1) pp. 163-169. Peer-reviewed.
 
Neuro-oncology of Neurofibromatosis Type 1.
Hottinger A.F., Khakoo Y., 2009. Current Treatment Options In Neurology, 11 (4) pp. 306-314. Peer-reviewed.
 
Neurological outcome of long-term glioblastoma survivors.
Hottinger A.F., Yoon H., DeAngelis L.M., Abrey L.E., 2009. Journal of Neuro-oncology, 95 (3) pp. 301-305. Peer-reviewed.
 
Neurooncology of familial cancer syndromes.
Hottinger A.F., Khakoo Y., 2009. Journal of Child Neurology, 24 (12) pp. 1526-1535. Peer-reviewed.
 
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Stupp R., Hottinger A.F., van den Bent M.J., Dietrich P.Y., Brandes A.A., 2008. Annals of Oncology, 19 (Suppl 7) pp. vii209-vii216. Peer-reviewed.
 
Management of malignant glioma--quo vadis?
Stupp R., Hottinger A.F., 2008. Onkologie, 31 (6) pp. 300-302. Peer-reviewed.
 
Stratégies thérapeutiques pour le traitement des gliomes [Therapeutic strategies for the management of gliomas]
Hottinger A.F., Stupp R., 2008. Revue Neurologique, 164 (6-7) pp. 523-30. Peer-reviewed.
 
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
Hottinger A.F., DeAngelis L.M., Yahalom J., Abrey L.E., 2007. Neurology, 69 (11) pp. 1178-1182. Peer-reviewed.
 
Update on the management of familial central nervous system tumor syndromes.
Hottinger A.F., Khakoo Y., 2007. Current Neurology and Neuroscience Reports, 7 (3) pp. 200-207. Peer-reviewed.
 
Combined femoral and obturator neuropathy caused by synovial cyst of the hip.
Stuplich M., Hottinger A.F., Stoupis C., Sturzenegger M., 2005. Muscle and Nerve, 32 (4) pp. 552-554. Peer-reviewed.
Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus.
Hottinger A.F., Azzouz M., Déglon N., Aebischer P., Zurn A.D., 2000/08. Journal of Neuroscience, 20 (15) pp. 5587-5593.
 
Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2
Azzouz M., Hottinger A., Paterna J. C., Zurn A. D., Aebischer P., Bueler H., 2000/03. Human Molecular Genetics, 9 (5) pp. 803-11.
 
Cellular xenotransplantation.
Aebischer P., Hottinger A.F., Déglon N., 1999. Nature Medicine, 5 (8) p. 852.
 
Treatment of diseases of the central nervous system using encapsulated cells.
Hottinger A.F., Aebischer P., 1999. Advances and Technical Standards In Neurosurgery, 25 pp. 3-20. Peer-reviewed.
 
The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
Hottinger A. F., Fine E. G., Gurney M. E., Zurn A. D., Aebischer P., 1997/07. European Journal of Neuroscience, 9 (7) pp. 1548-51.
 
Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders.
Hof P.R., Nimchinsky E.A., Buée-Scherrer V., Buée L., Nasrallah J., Hottinger A.F., Purohit D.P., Loerzel A.J., Steele J.C., Delacourte A., 1994. Acta Neuropathologica, 88 (5) pp. 397-404. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University